OncoDaily GI spotlights the innovations transforming gastrointestinal oncology — from precision biomarkers to advances in equitable cancer care. The second week of October features breakthroughs across colorectal, hepatobiliary, pancreatic, and esophageal cancers, underscoring the momentum of science and collaboration in reshaping the field.
Highlights include new evidence supporting curative surgery in recurrent colon cancer, deeper insights into colorectal cancer subtypes, and progress in pancreatic oncology through biomarker-guided immunotherapy, transcriptomic-driven chemotherapy, and early-detection models. Economic analyses in hepatocellular carcinoma strengthen value-based decision-making, while a European trial expands targeted treatment options for KRAS-mutant CRC.